BREAKING ALERT: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOA NEW YORK, Feb. 15, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma...

ROSEN, RESPECTED INVESTOR COUNSEL, Continues Its Investigation of Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Sonoma...

ROSEN, RESPECTED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma...

SONOMA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Sonoma Pharmaceuticals, Inc. on Behalf of Sonoma Stockholders and Encourages Investors to Contact the Firm NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sonoma Pharmaceuticals,...

Sonoma Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2017 Product revenue for fourth quarter up 60% and for fiscal year 2017 up 48%, compared to last year, driven by growth in U.S. dermatology salesCash position of $17.5 million; management believes the...